PHARMACY

DSNTV: Menasha’s Paul Murphy talks solutions for improving care, front-end sales

BY DSN STAFF

As retailers work to establish a continuum of patient care between the pharmacy back-bench and the front-end categories, Menasha has created a solution to educate pharmacists about front-of-store items that can not only provide better care for patients with chronic conditions and improve adherence, but also encourage basket-building among patients.

For this installment of DSN’s Executive Viewpoint series, DSN spoke to Menasha’s Paul Murphy, senior director of retail sales and new business development, about how Menasha is working to bridge the merchandising strategy gap between pharmacists and front-of-store, which can help improve care.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Valeant acquires ‘female Viagra’ maker Sprout

BY David Salazar

LAVAL, Quebec and RALEIGH, N.C. — Valeant Pharmaceuticals announced that it would be acquiring Sprout Pharmaceuticals. The acquisition will be for $1 billion in cash, plus a share of future profits given some milestones are achieved.

The news of the acquisition comes a day after Sprout received FDA approval for its Addyi  (filbanserin), a treatment for premenopausal women with generalized hypoactive sexual desire disorder (HSDD) — dubbed “female Viagra” by many in the lead-up to its approval.

“Delivering a first-ever treatment for a commonly reported form of female sexual dysfunction gives us the perfect opportunity to establish a new portfolio of important medications that uniquely impact women,” Valeant’s CEO and Chairman J. Michael Pearson said. “We applaud the efforts of the Sprout team to address this important area of unmet need and look forward to working with them to bring the benefits of Addyi to additional markets around the world.”

Sprout’s headquarters in North Carolina will become a Valeant division and Sprout CEO Cindy Whitehead will oversee it and Addyi’s commercialization, reporting to Valeant’s EVP and Company Group Chairman Anne Whitaker.

“I am extremely proud of the commitment and passion of our 34 employees who have been mission-driven to get to this breakthrough first for women,” Whitehead said. “This partnership with Valeant allows us the capacity to now ensure broader, more affordable access to all the women who have been waiting for this treatment.  Beyond building this in the United States, Valeant also offers us a global footprint that could eventually bring Addyi to women across the globe."

Valeant expects Addyi to be available in the fourth quarter of 2015 and it will be distributed through pharmacies and prescribers certified under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) that is in place to ensure the drug’s safe use. Valeant will also offer certification for prescribers and pharmacies once the transaction closes.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Focus on chronic care increases patient visits

BY DSN STAFF

While the first retail clinics began to enter chronic disease management going back as early as 2010, these efforts have been ramped up considerably in recent years as payers look more aggressively to lower costs and health systems look to drive improved patient outcomes.

(Click here to view the full Category Review.)

“Retailers are increasing their service offerings to include health screenings and chronic care programs,” noted the April 2015 Robert Wood Johnson Foundation report, “Building a culture of health: The value proposition of retail clinics.”

The report noted several key examples, including the following:

CVS MinuteClinic: Diabetes management services, including, glucose, hemoglobin A1C, blood pressure, weight management, and foot exams, as well as asthma maintenance therapy. In addition, the RWJF report also noted a partnership between MinuteClinic and Emory Healthcare to develop a series of protocols for hypertension evaluation, treatment and management to be used at Emory and MinuteClinic.

Walgreens Health Clinics: Assessment and management for diabetes, hypertension, high cholesterol and asthma.

ShopRite/QCare Clinic: Operates a behavioral health-screening kiosk in a store in an underserved Philadelphia community to help identify potential at-risk patients and provide referrals as needed.

“The increased focus on chronic care has resulted in a rise in the percentage of visits for screening and management of chronic conditions at [Walgreens Healthcare Clinics] from 4% in 2007 to 17% in 2013,” noted the RWJF report.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?